Trial Profile

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
Indications Diabetic macular oedema
Focus Therapeutic Use
Acronyms STAMP

Most Recent Events

01 Mar 2022 Planned End Date changed from 30 Oct 2020 to 30 Oct 2022.
01 Mar 2022 Planned primary completion date changed from 1 Jun 2020 to 1 Jul 2022.
14 Jan 2020 Planned End Date changed from 30 Oct 2019 to 30 Oct 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com